Skip to main content

Advertisement

Table 3 Kidney function before and after treatment

From: Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis

Study No. of patients Mean/Median eGFR (mL/min/1. 73m2)/ Serum Creatinine (mg/dL) at baseline Mean/Median eGFR (mL/min/1. 73m2)/ Serum Creatinine (mg/dL) after treatment P-value/Comments from investigator
Dumortier (2017) [18] 15 non-HD patients eGFR 29.0 (20–34) eGFR 27.0 (17–38) In non-HD patients, median eGFR was not significantly modified during treatment.
Taneja (2018) [22] 11 pre-dialysis patients eGFR 24.84 ± 3.96 eGFR 24.39 ± 3.63 0.82
Creatinine2.52 ± 0.35 Creatinine 2.56 ± 0.36 0.81
Singh(2017) [34] 36 eGFR 12.02 ± 6.89 eGFR 12.33 ± 6.10 0.77
Cox-North (2017) [35] NA patients not receiving dialysis eGFR 22.2 creatinine 3.1 eGFR 20 creatinine 3.3 1.0